# Comar

Comar is an Asset Manager based in Voorhees, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Voorhees, United States
- **Region:** North America
- **Address:** Voorhees, NJ, United States
- **Founded:** 1936
- **Assets under management:** Undisclosed
- **Website:** comar.com
- **LinkedIn:** https://www.linkedin.com/company/comar-inc

## Regulatory record

- **Reports private funds:** No

## About

Comar is a specialty packaging and dispensing provider based in Voorhees Township, United States, established in 1949. The company has not received external funding.

## Sectors

- Healthcare Services

## People

- Mike Ruggieri — President and CEO

## Questions

### Who owns Comar, and how is it governed?

Morgan Stanley Capital Partners acquired a majority stake in Comar in 2018. The firm operates as a privately held portfolio company with Mike Ruggieri as President and CEO. Prior to Morgan Stanley's acquisition, the company was family-run for multiple generations.

### What makes Comar's packaging a structural moat for its pharmaceutical customers?

Many of Comar's dispensing products, such as the DiversaPak oral syringe for generic Suboxone, are co-developed with pharma manufacturers and referenced directly in FDA drug applications. Changing the packaging requires a new regulatory filing, which creates an extremely high switching cost and near-captive demand for the life cycle of the drug.

### Does Comar focus exclusively on pharmaceutical packaging?

No. While pharmaceutical packaging—especially dispensing systems for addiction-treatment drugs—is its highest-moat segment, Comar also manufactures rigid plastic containers, closures, and dropper assemblies for consumer health, personal care, and food-and-beverage markets. Its medical division is the primary growth driver.

### How has Comar expanded its product capabilities recently?

Comar acquired iCanDose in 2022 to add patented child-resistant dispensing technology to its platform. In early 2024, the company launched a new line of eliquid dispensing closures designed for precision dosing in over-the-counter cough-and-cold and liquid vitamin products.

### Which pharmaceutical tailwinds most affect Comar's business?

Comar's fortunes are tied to the opioid-dependence treatment market, where generic buprenorphine/naloxone volumes rise with public-health policy changes that expand access. Increased FDA scrutiny on medication errors also drives demand for Comar's metered, child-resistant dispensing products in consumer health.

## Related profiles

- [Columbus Nova Technology Partners](https://altss.com/profile/columbus-nova-technology-partners)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/comar

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology